Letrozole Tablet, Film Coated
Product Images NDC 68071-5264

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 68071-5264). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5264 3)

Label for Letrozole 2.5 mg film-coated tablets manufactured by NuCare Pharmaceuticals, Inc. The label indicates a quantity of 30 tablets. It includes warnings to keep out of reach of children, storage instructions at controlled temperatures between 59-86°F, and mentions the manufacturer Intas Pharmaceuticals Limited in Ahmedabad, India. The label also contains various identification codes and barcodes.*

FDA Label Image

Figure 1 Disease-free Survival (median Follow-up 73 Months, Itt Approach) (Letrozole Fig1)

A line chart comparing treatment outcomes over 72 months for Letrozole and Tamoxifen. The y-axis represents survival probability (0.0 to 1.0), and the x-axis shows time in months. Two lines represent Letrozole (solid) and Tamoxifen (dashed), with Letrozole showing a slightly higher survival curve. Patient numbers at risk are noted below the graph for both treatments over time.*

FDA Label Image

Figure 2 Kaplan-meier Estimates Of Time To Progression (tamoxifen Study) (Letrozole Fig2)

A line graph showing progression-free survival over time in months. The graph compares Letrozole 2.5 mg tablets with Tamoxifen 20 mg, with progression-free proportion on the vertical axis ranging from 0 to 1 and time in months on the horizontal axis up to 60 months.*

FDA Label Image

Figure 3 Survival By Randomized Treatment Arm (Letrozole Fig3)

A survival curve chart comparing the proportion alive over months between letrozole and tamoxifen treatments. The x-axis represents time in months, ranging from 0 to 60, and the y-axis shows the proportion alive from 0.0 to 1.0. Two lines indicate survival trends for letrozole (solid line) and tamoxifen (dashed line), with both decreasing over time and crossing around 36 months.*

FDA Label Image

Figure 4 Kaplan-meier Estimates Of Time To Progression (megestrol Acetate Study) (Letrozole Fig4)

A Kaplan-Meier survival curve chart showing time to progression in days for different treatment groups of letrozole tablets. The chart compares letrozole 0.5 mg, letrozole 2.5 mg, and a group labeled MA, illustrating their respective progression rates over time.*

FDA Label Image

Figure 5 Kaplan-meier Estimates Of Time To Progression (aminoglutethimide Study) (Letrozole Fig5)

A survival curve chart showing time to progression (in days) for treatment groups receiving Letrozole tablets at different doses (0.5 mg, 2.5 mg) and a comparator labeled AG. The y-axis represents the proportion of subjects without progression, decreasing over time on the x-axis up to 1000 days.*

FDA Label Image

Letrozole Structural Formula (Letrozole Str)

Chemical structure diagram of letrozole, showing the molecular arrangement of its atoms and bonds as commonly depicted in pharmaceutical labeling.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.